A CML TKI drug being developed called ABL001 is worth watching. This TKI drug, if it works, will target more specifically just ABL (as in BCR-ABL), so the side effects caused by current TKI drugs which inhibit more than BCR-ABL would be significantly reduced. This is what I have long asked about: why can't we have a drug that simply targets the BCR-ABL more specifically rather than live with the side effects of also targeting c-KIt, PDGFR, SRC, etc, etc? Maybe we will finally get a drug with minimal side effects, which would also have minimal long-term secondary impact on the body. This would make ABL001 a great long term maintenance drug.
ABL001 is being tested for use in TKI combo therapy along with Tasigna to overcome resistance, which shows promise. Since ABL001 fits into a different part of the BCR-ABL than other CML TKI drugs, the resistance caused by losing effectiveness in the one TKI pocket would be overcome by ABL001 in the secondary TKI pocket. It would also overcome T315i and other difficult kinase mutations.
If ABL001 works, it is something that is very much needed for both initial TKI combo therapy -- which would yield a faster, deeper response -- and would also serve as a long term "mild" TKI maintenance drug.
I like this a lot. Hope it works out.
Clinical trials are recruiting world-wide:
Edited by Trey, 14 September 2016 - 04:29 PM.